

March 26, 2015

Dear Editor,

Please find enclosed the edited manuscript in Word format (file name: 16401-original article.doc).

Title: Transcatheter arterial infusion for advanced hepatocellular carcinoma; who are candidates?

Author: Eiichiro Suzuki, Tetsuhiro Chiba, Yoshihiko Ooka, Sadahisa Ogasawara, Akinobu Tawada, Tenyu Motoyama, Noya Kanogawa, Tomoko Saito, Masaharu Yoshikawa, Osamu Yokosuka

Name of Journal: *World Journal of Gastroenterology*

ESPS Manuscript NO: 16401

The manuscript has been improved according to the suggestions of reviewers:

1 Format has been updated

2 Revision has been made according to the suggestions of the reviewer (Page 9, Lines 6-10, underlined)

3 References and typesetting were corrected

Thank you again for publishing our manuscript in the *World Journal of Gastroenterology*.

Sincerely yours,

Tetsuhiro Chiba, MD, PhD

Department of Gastroenterology and Nephrology

Graduate School of Medicine, Chiba University

1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan

Tel: +81-43-2262083

Fax: +81-43-2262088

E-mail: techiba@faculty.chiba-u.jp

Re: Journal Editor-in-Chief,

April 28, 2015

Dear Editor,

Please find enclosed the edited manuscript in Word format (file name: 16401-original article.doc).

Title: Transcatheter arterial infusion for advanced hepatocellular carcinoma; who are candidates?

Author: Eiichiro Suzuki, Tetsuhiro Chiba, Yoshihiko Ooka, Sadahisa Ogasawara, Akinobu Tawada, Tenyu Motoyama, Naoya Kanogawa, Tomoko Saito, Masaharu Yoshikawa, Osamu Yokosuka

Name of Journal: *World Journal of Gastroenterology*

ESPS Manuscript NO: 16401

The manuscript has been improved according to the suggestions of associate reviewer.

1 The indications for TAI, especially compared to TACE.

Reply: According to your comment, we have described this point on Page 6, Lines 5–7 from the bottom (underlined).

2 Similarly, why did the authors change from TACE to TAI in some of their patients?

Reply: Thank you for your important comment. We have described this point with the indication for TAI on Page 6, Lines 5–7 from the bottom (underlined).

3 Patient's number by the BCLC staging system.

Reply: According to your comment, we have described the number of patients based on Barcelona Clinic Liver Cancer (BCLC) staging on Page 8, Lines 5–7 (underlined).

4 Rationale for selecting the chemotherapeutic agents.

Reply: We described this point on Page 6, Lines 1–5 from the bottom (underlined).

5 Number of patients who underwent TAI via an implantable chemoport.

Reply: We have described the number of patients receiving hepatic arterial infusion chemotherapy (HAIC) using an implanted port-catheter system on Page 8, Lines 8–9 (underlined).

6 In the abstract, the total number of patients categorized by sex was only 92.

Reply: We apologize for the incorrect description. We have corrected the number of female participants in the Abstract on Page 3, Line 7 from the bottom (underlined).

Thank you again for publishing our manuscript in the *World Journal of Gastroenterology*.

Sincerely yours,

Tetsuhiro Chiba, MD, PhD

Department of Gastroenterology and Nephrology

Graduate School of Medicine, Chiba University

1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan

Tel: +81-43-2262083

Fax: +81-43-2262088

E-mail: techiba@faculty.chiba-u.jp